← SynDRA
GSK-369796
SynDRA canonical compound SYN0004928 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | KCNH2 |
|---|
| Mechanism of action | potassium channel antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- potassium channel antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP2D6
- CYP1A2
- CYP2C19
- CYP2C8
- CYP2C9
- CYP3A4
Cross-references
Synonyms
- GSK 369796
- Gsk369796
- N-tert-butyl isoquine
- N-tert-butylisoquine
- Ntbisq
- BDBM50134936
- CHEMBL147806
- ZINC1912685
- GSK369796
- NTBISQ
- NSC8QP4B6Z
- RefChem:144524
- UNII-NSC8QP4B6Z
- SCHEMBL25994239
- SCHEMBL29711428
- GTPL10411
- DB-358733
- CS-7934
- AC-35394
- SCHEMBL31437932
- T7195
- orb1299990
- D80744
- MolPort-009-194-119
- EX-A2411
- AKOS015994550
- DB-325224
- DE-0055
- MFCD16627991
- GSK369796 diHCl
- S0188
- F867359
- UNII-6W7T5AWQ47
- GSK369796 2HCl
- KQB41121
- HY-12082A
- 6W7T5AWQ47
- Gsk369796 dihydrochloride
- GSK369796?
Look up GSK-369796 in the interactive SynDRA portal →